The use of tumor markers in testis cancer is low and varies considerably in the United States, despite the role markers can play in providing information pertinent to diagnosis, risk ...

Percent positivity for the primitive endodermal markers AFP and Glyp-3 and the mature endodermal markers TTF-1, CDX2, Hep Par 1, and Napsin A was compared within yolk sac tumor areas according to ...

The authors identified 4,742 cases of testicular cancer from the US population-based SEER database and evaluated the use of the tumor markers α-fetoprotein (AFP), human chorionic gonadotropin ...

QUESTION ASKED:The objective of this study is to evaluate the frequency of tumor marker use in patients with advanced solid tumors.SUMMARY ANSWER:Over a 1-year period, the mean number of any ...

The analysis was confined to patients with at least two precise marker assay results between days 7 and 22 from start of platinum-based combination chemotherapy, with at least 7 days between markers.

Alpha Cancer Technologies Presents New Data from ACT-903, an AFP-Maytansine Conjugate, in Online Publication at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting ...

Researchers uncover immune cell marker and regulator of anti-tumor immunity. ScienceDaily. Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2023 / 06 / 230623161126.htm.